FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  ORESHACK KURT					2. Issuer Name and Ticker or Trading Symbol  MARAVAI LIFESCIENCES HOLDINGS,  INC. [ MRVI ]									tionship of F all applicab Director	le)	Person(	10% Ov		
(Last) (First) (Middle) C/O MARAVAI LIFESCIENCES HOLDINGS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/29/2022								X	Officer (give title below)  General Couns			Other (s below)	specify	
10770 WATERIDGE CIRCLE, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year) 06/27/2022								- 1	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person				
(Street) SAN DIEGO	•														Form filed by More than One Reporting Person				g Person
(City)	(State)	(Zi <sub>l</sub>	p)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				nte onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)					ies Acquired (A) or Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount		(A) or (D)	Price	Transactio (Instr. 3 an				(Instr. 4)	
Class A Common Stock 04/2					29/2022				<b>A</b> <sup>(1)</sup>	V	394		A	\$22.95	25,931			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity (Instr. 3) or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amo Securities Unde Derivative Secu (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Embersion (B					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	•	Amount or Number of Shares		Transaction(s) (Instr. 4)			

## **Explanation of Responses:**

1. Amended to note that this a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 394 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

## Remarks:

/s/ Kurt Oreshack

06/27/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).